Should I buy Bio-Techne (TECH) stock or is it too late?
⭐ The most reliable of them, either direction: Stephens & Co. — 68% of its targets hit on this sector (99 calls tested). It aims for $73 (+0.7 %), call made on June 27, 2026, maturing on June 27, 2027 (62 d ago).
Firm-by-firm track record on Bio-Techne
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 100 % | +55.2 % | 5 | $65 -10% |
| Citigroup | 83 % | +21.7 % | 6 | $73 +1% |
| Stephens & Co. | 50 % | +10.9 % | 8 | $73 +1% |
| Baird | 50 % | +7.5 % | 10 | $73 +1% |
| Benchmark | 29 % | -3.6 % | 7 | $75 +3% |
| Keybanc | 20 % | -8.1 % | 5 | $90 +24% |
| Deutsche Bank | 67 % | +22.8 % | 6 | — |
| SVB Leerink | 33 % | +10.8 % | 6 | — |
✅ Reasons to believe
- Few solid positives from analysts right now: of 10 ratings, only 0 buys, and the median price target ($73) is barely above the price (+1%, at $72). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on TECH, Stifel (100% hit rate, 5 scored calls), only targets $65 (call made on February 5, 2026, maturing on February 5, 2027) (-10%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 10 ratings, 10 are neutral.
- Limited upside: the median target is only +1% from the current price.
- High valuation (P/E ~62): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Negligible dividend (0.5% yield): your return depends mostly on price appreciation.
The analyst consensus on TECH
Median target $73 (+1%) · 10 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Bio-Techne now?
We won't decide for you. The facts: 0% of analysts rate it a buy, median target $73 (+1%), and Stifel (most reliable on TECH, 100%) targets $65. Weigh that against valuation (P/E ~62). This is not personalized advice.
Is it too late to invest in Bio-Techne?
The stated upside is small: the median target ($73) sits just +1% from the price ($72) (most reliable on TECH: Stifel, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Bio-Techne still worth investing in?
It depends on the gap between the price ($72) and its estimated value: analysts target $73 on median (+1%), with 0% buys (most reliable on TECH: Stifel, 100%). Cross-check with their real reliability on TECH and the cautions above. Information, not advice.
What's the main risk in buying TECH?
Even the most reliable firm on TECH, Stifel (100% hit rate, 5 scored calls), only targets $65 (call made on February 5, 2026, maturing on February 5, 2027) (-10%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Bio-Techne profile (consensus, analyst reliability, price target, performance).